Our Clinical Development Program

Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.

We are also leveraging our background in bile acid chemistry to discover and develop other compounds.

*Investigational uses and have not been approved by the FDA or any other worldwide regulatory agency. Safety and efficacy have not been established.

± Intercept has a license to develop and commercialize in the U.S. only.

OCA = obeticholic acid; PBC = primary biliary cholangitis; NASH = nonalcoholic steatohepatitis; NDA = new drug application; sAH = severe alcohol-associated hepatitis; FXR = farnesoid X receptor; FDA = Food and Drug Administration